HangzhouS MedTech Future Growth
Future criteria checks 4/6
HangzhouS MedTech is forecast to grow earnings and revenue by 22.3% and 26.9% per annum respectively. EPS is expected to grow by 22.2% per annum. Return on equity is forecast to be 13.5% in 3 years.
Key information
22.3%
Earnings growth rate
22.2%
EPS growth rate
| Medical Equipment earnings growth | 26.5% |
| Revenue growth rate | 26.9% |
| Future return on equity | 13.5% |
| Analyst coverage | Low |
| Last updated | 25 Oct 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 1,076 | 431 | N/A | 402 | 2 |
| 12/31/2025 | 837 | 339 | N/A | 312 | 2 |
| 12/31/2024 | 651 | 270 | N/A | 247 | 2 |
| 9/30/2024 | 590 | 272 | 247 | 294 | N/A |
| 6/30/2024 | 567 | 263 | 216 | 268 | N/A |
| 3/31/2024 | 530 | 236 | 175 | 225 | N/A |
| 12/31/2023 | 509 | 217 | 170 | 221 | N/A |
| 9/30/2023 | 453 | 188 | 149 | 200 | N/A |
| 6/30/2023 | 419 | 169 | 136 | 182 | N/A |
| 3/31/2023 | 384 | 152 | 90 | 149 | N/A |
| 12/31/2022 | 371 | 145 | 96 | 156 | N/A |
| 12/31/2021 | 305 | 105 | 103 | 118 | N/A |
| 12/31/2020 | 172 | 45 | 25 | 53 | N/A |
| 12/31/2019 | 183 | 55 | 40 | 48 | N/A |
| 12/31/2018 | 122 | 37 | 14 | 43 | N/A |
| 12/31/2017 | 90 | 7 | N/A | 30 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 688581's forecast earnings growth (22.3% per year) is above the savings rate (2.8%).
Earnings vs Market: 688581's earnings (22.3% per year) are forecast to grow slower than the CN market (26.2% per year).
High Growth Earnings: 688581's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: 688581's revenue (26.9% per year) is forecast to grow faster than the CN market (13.9% per year).
High Growth Revenue: 688581's revenue (26.9% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 688581's Return on Equity is forecast to be low in 3 years time (13.5%).